Anticoagulant therapy: elimination of some commonly occurring pitfalls.

Abstract

Article1 March 1957ANTICOAGULANT THERAPY: ELIMINATION OF SOME COMMONLY OCCURRING PITFALLSARNOLD G. WARE, PH.D., ROBERT STRAGNELL, M.D.ARNOLD G. WARE, PH.D.Search for more papers by this author, ROBERT STRAGNELL, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-46-3-450 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe theoretic possibility of controlling thrombo-embolic disease with agents that inhibit blood clotting is well recognized. There is no question that undesirable thrombotic complications can be prevented when anticoagulant agents are properly utilized. However, the dangers resulting from this type of treatment appear in the literature1 all too frequently. Dicumarol has earned the reputation of being one of the most dangerous drugs in common use.2 This is indeed unfortunate, because this drug can be administered safely and effectively.One of the first essentials to successful anticoagulant therapy isproperlaboratory control. There are very few situations in clinical medicine where...Bibliography1. Editorial: Anticoagulants as a cause of hemorrhage, J. A. M. A. 144: 1466, 1950. CrossrefMedlineGoogle Scholar2. Flaxman N: Drug fatalities, J. A. M. A. 147: 377, 1951. CrossrefMedlineGoogle Scholar3. Quick AJ: The hemorrhagic diseases and the physiology of hemostasis, 1942, Charles C Thomas, Springfield, Illinois, p. 312. Google Scholar4. Owren PA: A quantitative one-stage method for the assay of prothrombin, Scandinav. J. Clin. and Lab. Invest. 1: 81, 1949. CrossrefMedlineGoogle Scholar5. WareStragnell AGR: An improved one-stage prothrombin method, Am. J. Clin. Path. 22: 791, 1952. CrossrefMedlineGoogle Scholar6. Owren PA, in Thrombosis and embolism, Proceedings of the 1st International Conference, 1954, Benno Schwabe & Co., Basel, p. 1222. Google Scholar7. GriffithStragnellLevinsonMooreWare GCRDCFJAG: A study of the beneficial effects of anticoagulant therapy in congestive heart failure, Ann. Int. Med. 37: 867, 1952. LinkGoogle Scholar8. OwrenAas PAK: The control of Dicumarol therapy and the quantitative determination of prothrombin and proconvertin, Scandinav. J. Clin. and Lab. Invest. 3: 201, 1951. CrossrefMedlineGoogle Scholar9. Owren PA: Long-term Dicumarol treatment in cardiovascular disease—technique and results, in Thrombosis and embolism, Proceedings of the 1st International Conference, 1954, Benno Schwabe & Co., Basel, p. 1085. Google Scholar10. Quick AJ: A new concept of venous thrombosis, Surg., Gynec. and Obst. 91: 296, 1950. MedlineGoogle Scholar11. Jorpes JE: Heparin in the treatment of thrombosis, 2nd Ed., 1946, Oxford University Press, London. Google Scholar12. Seegers WH: The influence of certain drugs on blood coagulation and related phenomena, Pharmacol. Rev. 3: 278, 1951. MedlineGoogle Scholar13. PortmanHolden AFWD: Protamine (salmine) sulfate, heparin, and blood coagulation, J. Clin. Investigation 28: 1451, 1949. CrossrefMedlineGoogle Scholar14. de Takats G: Anticoagulant therapy, Surgery 34: 985, 1953. MedlineGoogle Scholar15. BrownMacMillan KWRC: The choice of an anticoagulant, Am. J. M. Sc. 227: 526, 1954. CrossrefMedlineGoogle Scholar16. Pollock BE: Clinical experience with Warfarin (Coumadin) sodium, a new anticoagulant, J. A. M. A. 159: 1094, 1955. CrossrefMedlineGoogle Scholar17. StragnellWare RAG: Mephyton (emulsified vitamin K1) in the treatment of excessive therapeutic hypoprothrombinemia, M. Clin. North America 38: 413, 1954. CrossrefGoogle Scholar18. SmithSchelling FJV: A clinical comparison of laboratory methods used in controlling anticoagulant therapy, in Thrombosis and embolism, Proceedings of the 1st International Conference, 1954, Benno Schwabe & Co., Basel, p. 815. Google Scholar19. StefaniniDameshek MW: The hemorrhagic disorders, 1955, Grune & Stratton, New York, p. 302. Google Scholar20. AlexanderLandwehr BG: Evolution of a prothrombin conversion accelerator in stored human plasma and prothrombin fraction, Am. J. Physiol. 159: 322, 1949. CrossrefMedlineGoogle Scholar21. BanfiTanturiBay RFCAR: Prothrombin in preserved blood, J. Lab. and Clin. Med. 30: 512, 1945. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: *Received for publication May 25, 1956.From the Department of Biology and Nutrition, Department of Medicine, University of Southern California School of Medicine, and Laboratory Division of the Los Angeles County Hospital, Los Angeles, California.Requests for reprints should be addressed to Arnold G. Ware, Ph.D., P. O. Box 1120, Los Angeles County General Hospital, 1200 North State Street, Los Angeles 33, California. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAnticoagulant Therapy TodayComparison of continuous long-term heparin and oral anticoagulant therapy in patients with severe angina pectorisHeparin, its chemistry, pharmacology and clinical useDetermination of prothrombin concentration as an index of anticoagulant controlDicumarol TherapyCOAGULATION DEFECTS INDUCED BY LONG-TERM ANTICOAGULANT THERAPY*,†THE VALUE OF CONTINUOUS (1 TO 10 YEARS) LONG-TERM ANTICOAGULANT THERAPY*BENJAMIN MANCHESTER, F.A.C.P. 1 March 1957Volume 46, Issue 3Page: 450-456KeywordsAnticoagulant therapyAnticoagulantsBlood coagulationDrugsHospital medicineNutritionResearch laboratories ePublished: 1 December 2008 Issue Published: 1 March 1957 PDF downloadLoading ...